Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19007030 | 0.84 | EGFR (0.62) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL17127693 | 0.77 | EGFR (0.66) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL17127746 | 0.76 | EGFR (0.68) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL4774229 | 0.69 | L3MBTL1 (0.69) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL4764012 | 0.69 | KMT2A (0.65) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL849945 | 0.68 | KMT2A (0.59) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL3324450 | 0.68 | KMT2A (0.59) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL12941833 | 0.68 | AOC2 (0.56) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL24590292 | 0.67 | PLCG1 (0.44) | ALDH1A1 | |
| SCHEMBL4769268 | 0.67 | HPGD (0.73) | KMT2AMEN1L3MBTL1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | EGFR 1273/4885ERBB2 567/4885KMT2A 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.